Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $88.29 Consensus Target Price from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received an average rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is […]
More Stories
Israel, Turkey Continue Dispute Over Syria After Airbase Strike
By Evgenia Filimianova Israel and Turkey have deepened their dispute over Syria after Israel defended its strike on a Syrian...
First Lady Unveils Racing Collaboration, $2 Million in ‘Fostering the Future’ Scholarships
By Travis Gillmore WASHINGTON—First Lady Melania Trump held her first public event in about two months at the White House...
US Unemployment Claims Unexpectedly Dropped Last Week
By Andrew Moran The number of Americans submitting applications for unemployment benefits unexpectedly declined last week for the first time...
A Tale of 2 Straits: Global Shippers Prefer Washington’s Version Over Tehran’s
By John Haughey With the Aug. 17 expiration of the 60-day memorandum of understanding between the United States and Iran,...
Karmelo Anthony Seeks Retrial in Texas Track Meet Stabbing Case
By Stacy Robinson Karmelo Anthony is asking a newly appointed Texas judge to grant him a retrial after he was...
UAE Halts All Iranian Trade After 2 Missiles Launched From Iranian Territory
By Jill McLaughlin The United Arab Emirates (UAE) halted all trade with Iran after officials determined two missiles detected earlier...